ENTECAVIR (entecavir) by Molecular Devices is 12. Approved for chronic hepatitis b virus infection in adults, children at least 2 years of age with evidence of active viral replication, either evidence of persistent elevations in serum aminotransferases (alt and 3 more indications. First approved in 2017.
Drug data last refreshed 20h ago
12.1 Mechanism of Action Entecavir is an antiviral drug against hepatitis B virus [see Micribiology (12.4) ]. 12.3 Pharmacokinetics The single- and multiple-dose pharmacokinetics of entecavir were evaluated in healthy subjects and subjects with chronic hepatitis B virus infection. Absorption…
Worked on ENTECAVIR at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy
A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B
A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir
A Study of TQ-A3334 Combined With Entecavir in the Treatment of Chronic Hepatitis B
An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis b Who Have Received Nucleoside (Acid) Therapy